Lois C Orton1, Aika A A Omari. 1. School of Nursing, Midwifery and Social Work, University of Manchester, University Place, Oxford Road, Manchester, UK, M13 9PL. Lois.Orton@manchester.ac.uk
Abstract
BACKGROUND: Women are more vulnerable to malaria during pregnancy, and malaria infection may have adverse consequences for the fetus. Identifying safe and effective treatments is important. OBJECTIVES: To compare the effects of drug regimens for treating uncomplicated falciparum malaria in pregnant women. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group Specialized Register (February 2008), CENTRAL (The Cochrane Library 2008, Issue 1), MEDLINE (1966 to February 2008), EMBASE (1974 to February 2008), LILACS (February 2008), mRCT (February 2008), reference lists, and conference abstracts. We also contacted researchers in the field, organizations, and pharmaceutical companies. SELECTION CRITERIA: Randomized and quasi-randomized controlled trials of antimalarial drugs for treating uncomplicated malaria in pregnant women. DATA COLLECTION AND ANALYSIS: Two authors assessed trial eligibility and risk of bias, and extracted data. We performed a quantitative analysis only where we could combine the data. We combined dichotomous data using the risk ratio (RR) and presented each result with a 95% confidence interval (CI). MAIN RESULTS: Ten trials (1805 participants) met the inclusion criteria. Two were quasi-randomized, seven did not describe allocation concealment, and all adjusted treatment failure to exclude new infections. One trial reported fewer treatment failures at day 63 with artesunate plus mefloquine compared with quinine (RR 0.09, 95% CI 0.02 to 0.38; 106 participants). One trial reported fewer treatment failures at day 63 with artesunate plus atovaquone-proguanil compared with quinine (RR 0.14, 95% CI 0.03 to 0.57; 80 participants). One trial reported fewer treatment failures at day 28 when amodiaquine was compared with chloroquine (RR 0.20, 95% CI 0.08 to 0.46; 420 participants) and when amodiaquine plus sulfadoxine-pyrimethamine was compared with chloroquine (RR 0.02, 95% CI 0.00 to 0.26; 418 participants). Compared with sulfadoxine-pyrimethamine given alone, one trial reported fewer treatment failures at delivery (or day 40) with artesunate plus sulfadoxine-pyrimethamine (RR 0.15, 95% CI 0.04 to 0.59; 79 participants) and azithromycin plus sulfadoxine-pyrimethamine (RR 0.27, 95% CI 0.10 to 0.76; 82 participants). AUTHORS' CONCLUSIONS: Data are scant. Some combination treatments appear to be effective at treating malaria in pregnancy; however, safety data are limited.
BACKGROUND:Women are more vulnerable to malaria during pregnancy, and malaria infection may have adverse consequences for the fetus. Identifying safe and effective treatments is important. OBJECTIVES: To compare the effects of drug regimens for treating uncomplicated falciparum malaria in pregnant women. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group Specialized Register (February 2008), CENTRAL (The Cochrane Library 2008, Issue 1), MEDLINE (1966 to February 2008), EMBASE (1974 to February 2008), LILACS (February 2008), mRCT (February 2008), reference lists, and conference abstracts. We also contacted researchers in the field, organizations, and pharmaceutical companies. SELECTION CRITERIA: Randomized and quasi-randomized controlled trials of antimalarial drugs for treating uncomplicated malaria in pregnant women. DATA COLLECTION AND ANALYSIS: Two authors assessed trial eligibility and risk of bias, and extracted data. We performed a quantitative analysis only where we could combine the data. We combined dichotomous data using the risk ratio (RR) and presented each result with a 95% confidence interval (CI). MAIN RESULTS: Ten trials (1805 participants) met the inclusion criteria. Two were quasi-randomized, seven did not describe allocation concealment, and all adjusted treatment failure to exclude new infections. One trial reported fewer treatment failures at day 63 with artesunate plus mefloquine compared with quinine (RR 0.09, 95% CI 0.02 to 0.38; 106 participants). One trial reported fewer treatment failures at day 63 with artesunate plus atovaquone-proguanil compared with quinine (RR 0.14, 95% CI 0.03 to 0.57; 80 participants). One trial reported fewer treatment failures at day 28 when amodiaquine was compared with chloroquine (RR 0.20, 95% CI 0.08 to 0.46; 420 participants) and when amodiaquine plus sulfadoxine-pyrimethamine was compared with chloroquine (RR 0.02, 95% CI 0.00 to 0.26; 418 participants). Compared with sulfadoxine-pyrimethamine given alone, one trial reported fewer treatment failures at delivery (or day 40) with artesunate plus sulfadoxine-pyrimethamine (RR 0.15, 95% CI 0.04 to 0.59; 79 participants) and azithromycin plus sulfadoxine-pyrimethamine (RR 0.27, 95% CI 0.10 to 0.76; 82 participants). AUTHORS' CONCLUSIONS: Data are scant. Some combination treatments appear to be effective at treating malaria in pregnancy; however, safety data are limited.
Authors: N J White; F Nosten; S Looareesuwan; W M Watkins; K Marsh; R W Snow; G Kokwaro; J Ouma; T T Hien; M E Molyneux; T E Taylor; C I Newbold; T K Ruebush; M Danis; B M Greenwood; R M Anderson; P Olliaro Journal: Lancet Date: 1999-06-05 Impact factor: 79.321
Authors: F Nosten; M Vincenti; J Simpson; P Yei; K L Thwai; A de Vries; T Chongsuphajaisiddhi; N J White Journal: Clin Infect Dis Date: 1999-04 Impact factor: 9.079
Authors: C Menendez; J Ordi; M R Ismail; P J Ventura; J J Aponte; E Kahigwa; F Font; P L Alonso Journal: J Infect Dis Date: 2000-05-15 Impact factor: 5.226
Authors: R McGready; T Cho; N K Keo; K L Thwai; L Villegas; S Looareesuwan; N J White; F Nosten Journal: Clin Infect Dis Date: 2001-11-09 Impact factor: 9.079
Authors: R McGready; A Brockman; T Cho; D Cho; M van Vugt; C Luxemburger; T Chongsuphajaisiddhi; N J White; F Nosten Journal: Trans R Soc Trop Med Hyg Date: 2000 Nov-Dec Impact factor: 2.184
Authors: Teshome Gebre; Berhan Ayele; Mulat Zerihun; Jenafir I House; Nicole E Stoller; Zhaoxia Zhou; Kathryn J Ray; Bruce D Gaynor; Travis C Porco; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan Journal: Am J Trop Med Hyg Date: 2011-09 Impact factor: 2.345
Authors: Mariangela Bonizzoni; Yaw Afrane; Frederick N Baliraine; Dolphine A Amenya; Andrew K Githeko; Guiyun Yan Journal: Infect Genet Evol Date: 2009-05-04 Impact factor: 3.342
Authors: Zeno Bisoffi; Halidou Tinto; Bienvenu Sodiomon Sirima; Federico Gobbi; Andrea Angheben; Dora Buonfrate; Jef Van den Ende Journal: PLoS One Date: 2013-03-05 Impact factor: 3.240
Authors: A Roca; C Oluwalana; A Bojang; B Camara; B Kampmann; R Bailey; A Demba; C Bottomley; U D'Alessandro Journal: Clin Microbiol Infect Date: 2016-03-26 Impact factor: 8.067